Author Archives: admin


Cell Therapy Can Be Fast and Easy: Just Add mRNA Nanocarriers … – Genetic Engineering & Biotechnology News

Essentially, nanoparticles carried a gene-editing tool to T cells of the immune system that snipped out their natural T-cell receptors, and then was paired with genes encoding a chimeric antigen receptor, or CAR, a synthetic molecule designed to attack cancer.

Next, nanoparticles were targeted to blood stem cells and equipped with mRNA that enabled the stem cells to multiply and replace blood cancer cells with healthy cells when used in bone marrow transplants.

Finally, nanoparticles were targeted to CAR T cells and equipped with Foxo1 mRNA, which signals the anticancer T cells to develop into a type of "memory" cell that is more aggressive and destroys tumor cells more effectively and maintains antitumor activity longer.

"Our goal is to streamline the manufacture of cell-based therapies," said lead author Matthias Stephan, M.D., Ph.D., a faculty member in the Fred Hutch Clinical Research Division and an expert in developing biomaterials. "In this study, we created a product where you just add it to cultured cells and that's itno additional manufacturing steps."

Dr. Stephan and his colleagues developed a nanoparticle delivery system to extend the therapeutic potential of mRNA, which delivers molecular instructions from DNA to cells in the body, directing them to make proteins to prevent or fight disease.

The researchers' approach was designed to zero in on specific cell typesT cells of the immune system and blood stem cellsand deliver mRNA directly to the cells, triggering short-term gene expression. It's called "hit-and-run" genetic programming because the transient effect of mRNA does not change the DNA, but it is enough to make a permanent impact on the cells' therapeutic potential.

Other attempts to engineer mRNA into disease-fighting cells have been tricky. The large messenger molecule degrades quickly before it can have an effect, and the body's immune system recognizes it as foreignnot coming from DNA in the nucleus of the celland destroys it.

Stephan and his Fred Hutch collaborators devised a workaround to those hurdles.

"We developed a nanocarrier that binds and condenses synthetic mRNA and protects it from degradation," Dr. Stephan explained. The researchers surrounded the nanoparticle with a negatively charged envelope with a targeting ligand attached to the surface so that the particle selectively homes in and binds to a particular cell type.

The cells swallow up the tiny carrier, which can be loaded with different types of man-made mRNA. "If you know from the scientific literature that a signaling pathway works in synergy, you could co-deliver mRNA in a single nanoparticle," Dr. Stephan elaborated. "Every cell that takes up the nanoparticle can express both."

The approach involves mixing the freeze-dried nanoparticles with water and a sample of cells. Within four hours, cells start showing signs that the editing has taken effect. Boosters can be given if needed. Made from a dissolving biomaterial, the nanoparticles are removed from the body like other cell waste.

"Just add water to our freeze-dried product," Dr. Stephan emphasized. Since it's built on existing technologies and doesn't require knowledge of nanotechnology, he intends for it to be an off-the-shelf way for cell-therapy engineers to develop new approaches to treating a variety of diseases.

The approach could replace labor-intensive electroporation, a multistep cell-manufacturing technique that requires specialized equipment and clean rooms. All the handling ends up destroying many of the cells, which limits the amount that can be used in treatments for patients.

Gentler to cells, the nanoparticle system developed by the Fred Hutch team showed that up to 60 times more cells survive the process compared with electroporation. This is a critical feature for ensuring enough cells are viable when transferred to patients.

"You can imagine taking the nanoparticles and injecting them into a patient; then you don't have to culture cells at all anymore," he asserted.

Dr. Stephan has tested the technology in cultured cells in the lab, but it's not yet available as a treatment. He is looking for commercial partners to move the technology toward additional applications and into clinical trials where it could be developed into a therapy.

See the original post here:
Cell Therapy Can Be Fast and Easy: Just Add mRNA Nanocarriers ... - Genetic Engineering & Biotechnology News

Gilead Makes Long-Awaited Splash With $12B Bet on Kite, Cell Therapy – Xconomy

Xconomy San Francisco

Investors have been waiting for years for Gilead Sciences to make another big splash. This morning, it finally did, agreeing to buy Kite Pharma for close to $12 billion in a significant bet on the success of an emerging, cutting edge type of cancer immunotherapy known as CAR-T.

Gilead (NASDAQ: GILD), of Foster City, CA, is paying $180 per share in cash for Santa Monica, CA-based Kite (NASDAQ: KITE), a 29 percent premium to the companys $139.10 per share closing price on Friday and a deal that values the company at $11.9 billion. Kite shares promptly climbed 16 percent, to $162 apiece, early Monday. The agreement was first reported by the Wall Street Journal. It is expected to close during the fourth quarter. Kites lead product, to treat desperate cases of non-Hodgkin lymphoma, is expected to get FDA approval by the end of 2017.

For Gilead, the acquisition shows a renewed effort by the big drugmaker to make a dent in the oncology field. Gilead is known for its HIV drugs and more recently hepatitis C treatments, thanks to an $11 billion buyout of Pharmasset in 2011 that gave it the mega-blockbuster drugs sofosbuvir (Sovaldi) and sofosbuvir-ledipasvir (Harvoni). But over the years, Gilead has also steadily made a series of business development moves in oncology, among them an acquisition of Calistoga Pharmaceutials that gave the company its first, and to this point, only marketed cancer drug, idelalisib (Zydelig). In 2016, the drug generated $168 million in sales.

Gilead has been hoping for much more than that in cancer, and the pressure for the company to do something significant to generate excitement about its future has been building over the past few years as competing hepatitis C treatments have arrived and eroded its market share. Shares of Gilead are down almost 40 percent from their all-time highs in the summer of 2015 as calls for Gilead to use its pile of cashit had $36.6 billion on hand at the end of Juneon a transformative deal have intensified.

Will the Kite buyout be the jumpstart Gilead has been searching for? The deal is a gamble on a field of high promise, but substantial risk: a type of cancer immunotherapy treatment known as CAR-T, in which a patients immune cells are removed, modified, and re-infused into the body to find and kill cancer. The approach has shown promise in certain forms of blood cancer, in some cases wiping out leukemias or lymphomas in patients at deaths door, and is close to its first FDA approval. Novartis (NYSE: NVS) could bring the first CAR-T product, CTL019, to market later this year, and Kites axicabtagene ciloleucel (or axi-cel for short) could follow close behind. Kite has also filed for approval of axi-cel in Europe; a decision is expected next year.

The acquisition of Kite establishes Gilead as a leader in cellular therapy and provides a foundation from which to drive continued innovation for people with advanced cancers, said Gilead president and CEO, John Milligan, in a statement.

Milligan added that the cell therapy field has advanced very quickly, to the point where the science and technology have opened a clear path toward a potential cure for patients. And Gilead appears to be going all in, saying in its statement that it wants to build an industry-leading cell therapy franchise. But there are lingering questions about CAR-Ts overall potential. It comes with safety risks, namely figuring out how to harness the altered cells without causing the body significant harm in the process. A common reaction to treatment, for instance, is an immune system reaction called cytokine release syndrome that has proven deadly in some cases. Kite and Seattle competitor Juno Therapeutics (NASDAQ: JUNO) have also seen certain instances of brain swellingJuno had to abandon its most advanced treatment after the side effect led to multiple deaths in clinical testing.

In addition, CAR-T treatments havent yet worked in solid tumors, which include more prevalent cancers of the breast and lung. They also involve a complex manufacturing process and are likely to be very expensive; their commercial prospects are uncertain.

We are encouraged that Gilead has finally executed an acquisition and we think that the Kite deal is a major strategic positive, wrote Barclays analyst Geoff Meacham, in a research note. [T]he question will be if Kite will be big enough to move the needle and re-accelerate earnings growth to Sovaldi/Harvoni-launch levels.

Heres more on CAR-Ts promise and the questions that lie ahead for its developers.

Gilead will hold a conference call this morning to discuss the deal.

Ben Fidler is Xconomy's Deputy Biotechnology Editor. You can e-mail him at bfidler@xconomy.com

Continue reading here:
Gilead Makes Long-Awaited Splash With $12B Bet on Kite, Cell Therapy - Xconomy

Sofa Vergara’s ex might finally be out of luck in his battle for custody … – Slate Magazine (blog)

Sofa Vergaras embryos are citizens of California.

Christopher Polk/Getty Images for TNT

After years of battling ex-fiance Sofa Vergara in court for custody of a pair of frozen embryos they once made together, condiment entrepreneur Nick Loeb might finally be out of luck. Last week, a federal judge in Louisiana dismissed Loebs suit, saying that the embryos are citizens of California, where Vergara and Loeb conceived and froze them. Thus, the judge ruled, embryos have no legal standing to sue in Louisiana, the only state that gives embryos the right to sue and be sued.

Christina Cauterucci is a Slate staff writer.

Embryos are frozen when they are just clumps of a few dozen cells, equivalent to a vaginally inseminated egg that would still take another week to become embedded in the uterine wall. Louisiana law deems these cells juridical personsnot quite human beings, but deserving of legal rights. In Louisiana, embryos are not merely property of the two people who made them, so any legal disputes must meet the best interest of the in vitro fertilized ovum.

Thats the most likely reason why Loeb sued Vergara in Louisiana, despite the fact that neither party maintains a residence there.* (Loeb says he chose the state because the couple broke up there; he dropped an earlier California suit because he didnt want to name his previous girlfriends whod had abortions.) Actually, Loeb didnt exactly sue Vergarathe embryos, Emma and Isabella, did. Plaintiff EMMA is a female human being at the embryonic stage of life, five days old developmentally, the right to live suit read, claiming that Vergara had effectively abandoned and chronically neglected her children by keeping them frozen in a medical tank since 2013. Though Vergara and Loeb had signed a contract when they were together agreeing that the embryos would never be implanted anywhere without both parties consent, Loeb wanted to nullify the agreement and implant them in a surrogate.

Over the past couple of years, the Vergara-Loeb embryo battle has become a proxy fight for anti-abortion advocates who think frozen embryos should be treated like people. Anti-abortion groups have funded or filed amicus briefs in the embryo disputes of split-up couples, including the case of a Missouri woman named Jalesia McQueen. In the middle of her own court battle over two frozen embryos (Noah and Genesis) with an ex-husband who wanted to dispose of them, McQueen founded an organization called Embryo Defense to advocate for all excess embryos in legal limbo. She aggregates news on the Vergara-Loeb case and uses their photos in images made for sharing on social media. The graphics say things like Sofia says its selfish to let the embryos be born without both parents being in a loving relationship. Shouldnt both parents just love the child? and Please pray for Sofia Vergara and those she called her frozen babies, that shed open her heart so they could be a blessing in her life. One pairs a picture of Loebs face with the question what about a fathers right to choose?

The concept of a fathers right to procreate without input from the woman whose egg created the embryo is a favorite rallying cry of the embryo-protector set. Loeb himself made this argument in a 2015 New York Times op-ed with the magnificent headline Sofa Vergaras Ex-Fianc: Our Frozen Embryos Have a Right to Live. A woman is entitled to bring a pregnancy to term even if the man objects, Loeb wrote. Shouldnt a man who is willing to take on all parental responsibilities be similarly entitled to bring his embryos to term even if the woman objects?

The federal judges decision against Loeb is only the latest in a string of disappointing court losses for those who believe embryos should be treated like people. When Barack Obama lifted a ban on federal funding for embryonic stem cell research in 2009, he was hit with a lawsuit from one Mary Scott Doe, a frozen embryo symbolizing all existing frozen embryos. A federal appeals court ruled that Doe had no standing as an amorphous class that could not prove any actual harm. In 2015, a California Superior Court judge ruled that a contract a divorced couple signed at the medical center where they created the embryo prevented either party from taking unilateral custody of the embryos unless one of the parties died. Even McQueen, the founder of Embryo Defense, lost her suit late last year when a St. Louis court ruled that embryos are marital property of a special character, not human beings with unalienable rights.

That St. Louis case might be the most promising decision yet for those who believe that no person should be able to incubate an embryo without the consent of the other person whose genetic material it carries. The others, which rest on the tenets of contract law, legal standing, and jurisdiction, say more about how the suits were filed than what rights adults have to the embryos they create. Still, Loebs loss could set a welcome precedent in these kinds of cases: Jurisdiction-shopping embryo protectors might find Louisiana to be a less hospitable home for a lawsuit than theyd imagined.

*Correction, August 31, 2017: This piece originally referred to "the most likely reason why Loeb sued Vergara in California, despite the fact that neither party maintains a residence there." It should have said Louisiana.

Read more from the original source:
Sofa Vergara's ex might finally be out of luck in his battle for custody ... - Slate Magazine (blog)

Ethical Stem Cells Relieve Parkinson’s in Monkeys – National Review

The advance of ethical stem cell research continues exponentially. Neurons made from induced pluripotent stem cellswhich were, in turn, made from skin cellshave relieved Parkinsons symptoms in monkeys. From the Nature story:

Takahashis team transformed iPS cells derived from both healthy people and those with Parkinsons into dopamine-producing neurons. They then transplanted these cells intomacaquemonkeys with a form of the disease induced by a neuron-killing toxin.

The transplanted brain cells survived for at least two years and formed connections with the monkeys brain cells, potentially explaining why the monkeys treated with cells began moving around their cages more frequently.

Crucially, Takahashis team found no sign that the transplanted cells had developed into tumours a key concern with treatments that involve pluripotent cells or that they evoked an immune response that couldnt be controlled with immune-suppressing drugs.

Human trials may begin in within a few years.

Two points about this, well three:

First, this study validates George W. Bushs prediction, when he placed mild limitations on federal embryonic stem cell funding,that scientists would be able to find ethical means of furthering regenerative medicine without using embryos.

Second, contrary to embryonic stem cells being the only hope, as so many Bush funding policy opponents claimed,embryonic stem cell research has not advanced nearly as far as adult stem cells and IPSCadvances have.

I keep bringing this up because all through the Bush terms in office, the scientists engaged in a mendacious campaign of hype and outright liesabout the potential and timing of treatments from embryonic stem cell research, as they poo-poohed the potential of alternative methods. But they were wrong and those who supported the Bush policy were right.

In other words, just because the Science Establishment says something, that doesnt make it so. Sometimes the scientists are wrong, or are conflating ideology with science, properly understood.

Third, contrary to animal rights ideologues and others, primate research is absolutely essential to furthering medical science. None of the potential we are seeing in this study could be known without testing on animals before humans.

So, lets hope that IPSCs and adult stem cells continue to advance into the clinical setting. They not only provide hope for efficacious treatmentslets not say curesbut offer a bridge across ethical divides that have roiled the field.

See original here:
Ethical Stem Cells Relieve Parkinson's in Monkeys - National Review

Are stems cells really the fountain of youth? – Star2.com – Star2.com

There are many claims that stem cells possess anti-ageing properties and other secrets to youth and regeneration. However, there has not been much scientific proof demonstrating these touted abilities.

Dr Paul Lucas, an assistant professor of orthopaedics and pathology from the New York Medical College in the United States, notes that the words stem cells are thrown around far too casually, and that many people assume that they are a single type of cell.

The definition of stem cell is an operational definition.

That is, it describes what the cell can do, and not any particular protein or other marker it can make, he says.

According to him, a stem cell is a cell that can:

Differentiate into at least one phenotype (cell type), and

Has the ability to divide, with at least one daughter cell remaining a stem cell.

Lots of hype, very little biology. I have written several answers on the website Quora that address this.

Pills and creams are not legit.

The skin has a barrier called the stratum corneum that prevents bacteria from getting inside the body.

The stratum corneum will also block stem cells, which are much, much larger than bacteria, in the form of a cream.

Any stem cell will not survive in a pill with no water. And of course, any cell will not survive the hydrochloric acid in the stomach.

So there is no way stem cells in either a pill or a cream can get inside the body.

Even if a stem cell could get inside the body, there is very little data that any stem cell will be anti-ageing its a way to separate people from their money.

There are several reasons stem cells do not counter ageing.

Stem cells are not magic. They are not magic pixie dust you can sprinkle on everything and make it be perfect.

Ageing has many causes. One of them is DNA and cellular damage.

It is thought that the various adult stem cells are the cells of origin of cancer. The data is very solid for at least hepatomas and leukaemias.

That means that stem cells can suffer mutations that alter cellular function degrading it in some cases, and causing it to go haywire and be cancer in others.

Also, how are stem cells to be injected? Into each tissue? Every muscle, organ, tendon, ligament, etc?

Or are the stem cells to be injected into a vein and travel to all parts of the body?

There are two technical problems with this:

Injecting into a vein means that most of the cells are going to be trapped in the lungs before they go out to the rest of the body, as our veins all lead first to our heart, then our lungs.

Blood vessels are sealed tubes. Think pipes.

Just how are the stem cells supposed to exit the pipes?

This is especially true for reversing ageing in the most important organ the brain.

The neural tissue in the brain is separated from the blood vessels by another layer of tissue called the blood-brain barrier.

Even if stem cells got out of the blood vessels in the brain, they are not going to get to the neural tissue, which is the tissue that needs to rejuvenate.

There is no way any injected stem cells are just going to magically replace all the aged cells in the body.

Stem cells are a class of undifferentiated cells that are able to differentiate into specialised cell types. Photo: 123rf.com

Plants are very different from us. No cell from a plant is going to be able to incorporate into our tissues and act like a stem cell.

Many mammalian stem cells particularly mesenchymal stem cells synthesise and secrete several proteins.

Some of these proteins are growth factors in that they cause other cells to divide.

The claim seems to be that plant growth factors will have the same effect on human cells as they do on plant cells.

That is false.

Even some of the skincare people admit this. The following quote is from the website of a US-based skincare company that uses both human and plant stem cells: That said, unlike human stem cells, the growth factors, cytokines and other proteins, which are the products of plant stem cells, do not have the ability to act in the same way in humans, as in plants.

Plant stem cells communicate in a different biochemical language that human cells do not recognise.

First is the source.

ESCs are the inner cell mass of a five to seven-day-old blastocyst, which is formed after the sperm successfully fertilises the egg.

PSCs come either from the tissue of the placenta itself or from the Whartons jelly of the umbilical cord.

Secondly, ESCs are pluripotent, meaning they are able to differentiate into every tissue of the body. They can also form tumours in our body.

PSCs are essentially adult stem cells that have limited proliferation potential, i.e. the cell has a fixed number of times it can divide before it dies. They are multipotent, meaning that they have the ability to form more than one cell type, and do not form tumours.

Probably less costly, but no more effective.

The treatment uses mesenchymal stem cells (MSCs).

The discoverer of MSCs Prof Dr Arnold Caplan says they should be called mesenchymal secreting cells. Notice that he does not consider them stem cells!

MSCs secrete a large number of cytokines that reduce inflammation. It is inflammation that causes pain.

Aspirin, ibuprofen, and naproxen also reduce inflammation.

A stem cell injection with MSCs is essentially putting little aspirin factories at the site of injury.

They reduce the pain, but do little or nothing to regenerate the tissue.

For young athletes, reducing inflammation will allow the bodys healing process to work better, and thus, improve outcome.

For older patients? There is less capacity for healing.

All comments are moderated. Your comment may not show up immediately. Please keep it clean and on topic. Offensive comments will not be published.

Read more here:
Are stems cells really the fountain of youth? - Star2.com - Star2.com

FDA announces actions regarding stem cell treatments – Lexology (registration)

Together with new guidance regarding the potential regulatory pathways for gene therapies, the FDA announced on Monday, August 28, 2017, that it will be taking action against companies providing unapproved stem cell treatments. This new guidance, combined with the threat of enforcement actions, provides the regenerative medicine industry and its partners with certain direction regarding the differences between pioneering stem cell therapies for which regulatory pathways are being crafted and unapproved treatments, which are likely to trigger scrutiny by the FDA.

Overview of enforcement actions

On August 24, the FDA issued a warning letter to a Florida clinic that recovered a patient's own adipose tissues, processed those tissues into stromal vascular fraction (SVF) i.e., adult stem cells derived from the patient's own fat and then administered the SVF to the patient for treatment of any one of several conditions, including Parkinson's disease, amyotrophic lateral sclerosis (ALS) and chronic obstructive pulmonary disease (COPD).

The FDA rejected the clinic's arguments that

Instead, the FDA took the position that the post-recovery processing of the adipose tissues takes the procedure outside of both the definition of an HCT/P and the same-surgical-procedure exception. The agency further noted that use of SVF for conditions such as Parkinson's disease, ALS and COPD do not meet the homologous use requirement of 21 CFR 1271.10. The agency also announced an action against a separate stem cell therapy clinic in California.

In light of these developments, practitioners and clinics who are

Guidance for regenerative medicine companies

While announcing these regulatory and enforcement actions, the FDA also sought to reassure the regenerative medicine industry of the agency's dedication to promoting this field of science. FDA Commissioner Scott Gottlieb wrote that the agency plans to "advance a comprehensive policy framework that will more clearly describe the rules of the road for this new field." Manifesting the agency's willingness to work with industry, Dr. Gottlieb noted that while "[m]any of the individualized treatments fall clearly outside the FDA's pre-market requirements[f]or those that currently fall across the line and are subject to the FDA's existing pre-market review, we want to make sure the process for gaining FDA approval is efficient. We want to facilitate innovation." Thus, while signaling its intent to take action against entities it believes are "targeting vulnerable patients," the FDA indicated that it "will give current product developers a very reasonable period of time to interact with the FDA in order to determine if they need to submit an application for marketing authorization and to come into the agency and work on a path towards approval."

The FDA also reaffirmed its commitment to fully implementing the regenerative medicine advanced therapy (RMAT) designation process. The designation is given to cell therapies, therapeutic tissue engineering products, human cell and tissue products, or any combination product using such therapies or products intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and for which preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such disease or condition. See Section 3033 of the 21st Century Cures Act.

These are important developments for stakeholders across the regenerative medicine industry, including:

Read more here:
FDA announces actions regarding stem cell treatments - Lexology (registration)

Six Japanese arrested over medical treatments using blood taken from umbilical cords, which are popular with Chinese … – South China Morning Post

Six people have been arrested in Japan over the illegal sale and use of blood from umbilical cords and placenta in regenerative medical treatments, with Chinese nationals reportedly the biggest foreign clients of clinics carrying out the procedures.

Police have referred Tsuneo Shinozaki, the head of a company that brokered the illegal sale of cord blood, to prosecutors, along with the head of a Tokyo regenerative medicine clinic and four others. The doctor has also been charged with breaking the law on regenerative medicine.

Blood taken from umbilical cords and placenta is high in blood-forming stem cells, which are used in treatments for leukaemia and other critical diseases. There are also hopes that research into regenerative medicine will find cures to cardiac and other complaints, and may even mitigate the effects of Parkinsons disease by implanting nerve cells into the brain.

Chinese people misunderstand stem cell treatments and they just see it as some sort of magic solution

Manager of a Tokyo clinic

There are, however, elevated risks of infection and graft rejection, meaning any procedures using cord blood require extensive testing to ensure compatibility and explicit authorisation from Japans health ministry.

Claims the blood is also an effective beauty treatment have not been proven but that has not put off more than 1,000 patients undergoing such procedures at facilities across Japan in recent years. It has also been claimed it is effective in treating cancer, although that suggestion also remains unproven to date.

The manager of a clinic in Kyoto told local media Chinese people who had learnt of regenerative therapies had travelled to Japan on organised medical tourism trips.

Chinese people misunderstand stem cell treatments and they just see it as some sort of magic solution to any health problems that they have, the manager of a Tokyo-based clinic told the South China Morning Post.

They come to Japan because this sort of treatment is not available in China and because Japan is seen as being advanced in this area and having good medical facilities, said the official, who declined to be named and insisted his facility did not conduct procedures using umbilical cord blood.

He added that, under Japanese law, clinics are limited in the services they are able to advertise on their websites, but some clinics take out advertisements in China through other companies, enabling them to evade scrutiny.

It is not illegal for Chinese people to travel abroad for medical procedures, including regenerative therapies.

According to investigators, illegal injections of umbilical cord blood were conducted at clinics and private hospitals in at least 20 prefectures across Japan, with about 30 per cent of the clients from overseas.

Facilities charged between 3 million yen (HK$212,500) and 4 million yen for each injection.

By law, umbilical cord blood is donated free of charge to publicly operated blood banks by women after they have given birth. The blood is kept in storage. Such banks have to be licensed and are closely regulated to ensure safety.

The blood used in the recent unmonitored treatments was obtained from a blood bank that went bankrupt. Brokers paid to obtain the blood and sold it on to clinics.

Excerpt from:
Six Japanese arrested over medical treatments using blood taken from umbilical cords, which are popular with Chinese ... - South China Morning Post

Dr Con Man: the rise and fall of a celebrity scientist who fooled almost everyone – The Guardian

Doctor Macchiarini fooled everyone, for a time. Photograph: TT News Agency/Press Association Images

Scientific pioneer, superstar surgeon, miracle worker thats how Paolo Macchiarini was known for several years. Dressed in a white lab coat or in surgical scrubs, with his broad, handsome face and easy charm, he certainly looked the part. And fooled almost everyone.

Macchiarini shot to prominence back in 2008, when he created a new airway for Claudia Castillo, a young woman from Barcelona. He did this by chemically stripping away the cells of a windpipe taken from a deceased donor; he then seeded the bare scaffold with stem cells taken from Castillos own bone marrow. Castillo was soon back home, chasing after her kids. According to Macchiarini and his colleagues, her artificial organ was well on the way to looking and functioning liked a natural one. And because it was built from Castillos own cells, she didnt need to be on any risky immunosuppressant drugs.

This was Macchiarinis first big success. Countless news stories declared it a medical breakthrough. A life-saver and a game-changer. We now know that wasnt true. However, the serious complications that Castillo suffered were, for a long time, kept very quiet.

Meanwhile, Macchiarinis career soared. By 2011, he was working in Sweden at one of the worlds most prestigious medical universities, the Karolinska Institute, whose professors annually select the winner of the Nobel prize in physiology or medicine. There he reinvented his technique. Instead of stripping the cells from donor windpipes, Macchiarini had plastic scaffolds made to order. The first person to receive one of these was Andemariam Beyene, an Eritrean doctoral student in geology at the University of Iceland. His recovery put Macchiarini on the front page of the New York Times.

Macchiarini was turning the dream of regenerative medicine into a reality. This is how NBCs Meredith Vieira put it in her documentary about Macchiarini, appropriately called A Leap of Faith: Just imagine a world where any injured or diseased organ or body part you have is simply replaced by a new artificial one, literally manmade in the lab, just for you. This marvelous world was now within reach, thanks to Macchiarini.

Last year, however, the dream soured, exposing an ugly reality.

Macchiarini gave his regenerating windpipes to 17 or more patients worldwide. Most, including Andemariam Beyene, are now dead. Those few patients who are still alive including Castillo have survived in spite of the artificial windpipes they received.

In January 2016, Macchiarini received an extraordinary double dose of bad press. The first was a Vanity Fair article about his affair with Benita Alexander, an award-winning producer for NBC News. She met Macchiarini while producing A Leap of Faith and was soon breaking one of the cardinal rules of journalism: dont fall in love with the subject of your story.

By the time the program aired, in mid-2014, the couple were planning their marriage. It would be a star-studded event. Macchiarini had often boasted to Alexander of his famous friends. Now they were on the wedding guest list: the Obamas, the Clintons, Vladimir Putin, Nicolas Sarkozy and other world leaders. Andrea Bocelli was to sing at the ceremony. None other than Pope Francis would officiate, and his papal palace in Castel Gandolfo would serve as the venue. Thats what Macchiarini told his fiancee.

But as the big day approached, Alexander saw these plans unravel, and finally realised that her lover had lied about almost everything. The pope, the palace, the world leaders, the famous tenor they were all fantasies.

Likewise the whole idea of a wedding: Macchiarini was still married to his wife of 30 years.

Macchiarinis deceit was so outlandish, Vanity Fair sought the opinion of the Harvard professor Ronald Schouten, an expert on psychopaths, who gave this diagnosis-at-a-distance: Macchiarini is the extreme form of a con man. Hes clearly bright and has accomplishments, but he cant contain himself. Theres a void in his personality that he seems to want to fill by conning more and more people.

Which left a big, burning question in the air: if Macchiarini was a pathological liar in matters of love, what about his medical research? Was he conning his patients, his colleagues and the scientific community?

The answer came only a couple of weeks later, when Swedish television began broadcasting a three-part expos of Macchiarini and his work.

Called Experimenten (The Experiments), it argued convincingly that Macchiarinis artificial windpipes were not the life-saving wonders wed all been led to believe. On the contrary, they seemed to do more harm than good something that Macchiarini had for years concealed or downplayed in his scientific articles, press releases and interviews.

Faced with this public relations disaster, the Karolinska Institute immediately promised to investigate the allegations but then, within days, suddenly announced that Macchiarinis contract would not be extended.

Macchiarinis fall was swift, but troubling questions remain about why he was allowed to continue his experiments for so long. Some answers have emerged from the official inquiries into the Karolinska Institute and the Karolinska University hospital. They identified many problems with the way the twin organisations handled him.

Macchiarinis fame had won him well-placed backers. These included Harriet Wallberg, who was the vice-chancellor of the Karolinska Institute in 2010, when Macchiarini was recruited. She pushed through his appointment despite the fact that he had some very negative references and dubious claims on his rsum.

This set a dangerous example. It showed department heads and colleagues that they should give Macchiarini special treatment.

He could do pretty much as he pleased. In the first couple of years at Karolinska, he put plastic airways into three patients. Since this was radically new, Macchiarini and his colleagues should have tested it on animals first. They didnt.

Likewise, they didnt undertake a proper risk assessment of the procedure, nor did Macchiarinis team seek government permits for the plastic windpipes, stem cells, and chemical growth factors they used. They didnt even seek the approval of Stockholms ethical review board, which is based at Karolinska.

Though Macchiarini was in the public eye, he was able to sidestep the usual rules and regulations. Or rather, his celebrity status helped him do so. Karolinskas leadership expected big things from their superstar, things that would bring prestige and funding to the institute.

They also cited a loophole known as compassionate use. Macchiarini, they claimed, wasnt really doing clinical research. No, he was just caring for his patients who were, one and all, facing certain death with no other treatment options available and no time to waste. In such dire circumstances, new treatments can be tried as a last resort.

This argument didnt wash with those who later investigated the case. In their view, Macchiarini was certainly engaged in clinical research. Besides which, compassionate concerns dont override the basic principles of patient safety and informed consent. Macchiarini, meanwhile, said he did not accept the findings of the disciplinary board.

As it turned out, Macchiarinis patients werent all at deaths door at the time he treated them. Andemariam Beyene, for instance, had recurrent cancer of the windpipe but, aside from a cough, was still in good health. But even if his days had been numbered, this didnt necessarily justify what Macchiarini put him through.

Beyenes death two and a half years after the operation, caused by the failure of his artificial airway, was a grueling ordeal. According to Pierre Delaere, a professor of respiratory surgery at KU Leuven, Belgium, Macchiarinis experiments were bound to end badly. As he said in Experimenten: If I had the option of a synthetic trachea or a firing squad, Id choose the last option because it would be the least painful form of execution.

Delaere was one of the earliest and harshest critics of Macchiarinis engineered airways. Reports of their success always seemed like hot air to him. He could see no real evidence that the windpipe scaffolds were becoming living, functioning airways in which case, they were destined to fail. The only question was how long it would take weeks, months or a few years.

Delaeres damning criticisms appeared in major medical journals, including the Lancet, but werent taken seriously by Karolinskas leadership. Nor did they impress the institutes ethics council when Delaere lodged a formal complaint.

Support for Macchiarini remained strong, even as his patients began to die. In part, this is because the field of windpipe repair is a niche area. Few people at Karolinska, especially among those in power, knew enough about it to appreciate Delaeres claims. Also, in such a highly competitive environment, people are keen to show allegiance to their superiors and wary of criticising them. The official report into the matter dubbed this the bandwagon effect.

With Macchiarinis exploits endorsed by management and breathlessly reported in the media, it was all too easy to jump on that bandwagon.

And difficult to jump off. In early 2014, four Karolinska doctors defied the reigning culture of silence by complaining about Macchiarini. In their view, he was grossly misrepresenting his results and the health of his patients. An independent investigator agreed. But the vice-chancellor of Karolinska Institute, Anders Hamsten, wasnt bound by this judgement. He officially cleared Macchiarini of scientific misconduct, allowing merely that hed sometimes acted without due care.

For their efforts, the whistleblowers were punished. When Macchiarini accused one of them, Karl-Henrik Grinnemo, of stealing his work in a grant application, Hamsten found him guilty. As Grinnemo recalls, it nearly destroyed his career: I didnt receive any new grants. No one wanted to collaborate with me. We were doing good research, but it didnt matter I thought I was going to lose my lab, my staff everything.

This went on for three years until, just recently, Grinnemo was cleared of all wrongdoing.

The Macchiarini scandal claimed many of his powerful friends. The vice-chancellor, Anders Hamsten, resigned. So did Karolinskas dean of research. Likewise the secretary-general of the Nobel Committee. The university board was dismissed and even Harriet Wallberg, whod moved on to become the chancellor for all Swedish universities, lost her job.

Unfortunately, the scandal is much bigger than Karolinska, which accounts for only three of the patients who have received Macchiarinis regenerating windpipes.

The other patients were treated at hospitals in Barcelona, Florence, London, Moscow, Krasnodar, Chicago and Peoria. None of these institutions have faced the same kind of public scrutiny. None have been forced to hold full and independent inquiries. They should be.

If the sins of Karolinska have been committed elsewhere, it is partly because medical research facilities share a common milieu, which harbours common dangers. One of these is the hype surrounding stem cells.

Stem cell research is a hot field of science and, according to statistics, also a rather scandal-prone one. Articles in this area are retracted 2.4 times more often than the average for biomedicine, and over half of these retractions are due to fraud.

Does the heat of stem cell research the high levels of funding, prestige and media coverage it enjoys somehow encourage fraud? Thats what our experience of medical research leads us to suspect. While there isnt enough data to actually prove this, we do have some key indicators.

We have, for example, a growing list of scientific celebrities who have committed major stem cell fraud. There is South Koreas Hwang Woo-suk who, in 2004, falsely claimed to have created the first human embryonic stem cells by means of cloning. A few years ago, Japans Haruko Obokata pulled a similar con when she announced to the world a new and simple and fake method of turning ordinary body cells into stem cells.

Hwang, Obokata and Macchiarini were all attracted to the hottest regions of stem cell research, where hope for a medical breakthrough was greatest. In Macchiarinis case, the hope was that patients could be treated with stem cells taken from their own bone marrow.

Over the years, this possibility has generated great excitement and a huge amount of research. Yet, for the vast majority of such treatments, there is little solid evidence that they work. (The big exception is blood stem cell transplantation, which has been saving the lives of people with leukemia and other cancers of the blood for decades.)

Its enough to worry officials from the US Food and Drug Administration (FDA). They recently published an article in the New England Journal of Medicine admitting that stem cell research has mostly failed to live up to its therapeutic promise.

An alarmingly wide gap has grown between what we expect from stem cells and what they deliver. Each new scientific discovery brings a flood of stories about how it will revolutionise medicine one day soon. But that day is always postponed. An unhappy result of this is the rise of pseudo-scientific therapies. Stem cell clinics have sprung up like weeds, offering to treat just about any ailment you can name. In place of clinical data, there are gushing testimonials. There are also plenty of desperate patients who believe because theyve been told countless times that stem cells are the cure, and who cannot wait any longer for mainstream medicine. They and their loved ones fall victim to false hope.

Scientists can also suffer from false hope. To some extent, they believed Macchiarini because he told them what they wanted to hear. You can see this in the speed with which his breakthroughs were accepted. Only four months after Macchiarini operated on Claudia Castillo, his results provisional but very positive were published online by the Lancet. Thereafter it was all over the news.

The popular press also has a lot to answer for. Its love of human interest stories makes it sympathetic to unproven therapies. As studies have shown, the media often casts a positive light on stem cell tourism, suggesting that the treatments are effective and the risks low. It did much the same for Macchiarinis windpipe replacements. A good example is the NBC documentary A Leap of Faith. Its fascinating to rewatch as a lesson on how not to report on medical science.

It is fitting that Macchiarinis career unravelled at the Karolinska Institute. As the home of the Nobel prize in physiology or medicine, one of its ambitions is to create scientific celebrities. Every year, it gives science a show-business makeover, picking out from the mass of medical researchers those individuals deserving of superstardom. The idea is that scientific progress is driven by the genius of a few.

Its a problematic idea with unfortunate side effects. A genius is a revolutionary by definition, a risk-taker and a law-breaker. Wasnt something of this idea behind the special treatment Karolinska gave Macchiarini? Surely, he got away with so much because he was considered an exception to the rules with more than a whiff of the Nobel about him. At any rate, some of his most powerful friends were themselves Nobel judges until, with his fall from grace, they fell too.

If there is a moral to this tale, its that we need to be wary of medical messiahs with their promises of salvation.

Go here to see the original:
Dr Con Man: the rise and fall of a celebrity scientist who fooled almost everyone - The Guardian

FDA Should Tread Carefully with Stem Cell Regulation – Pain News Network

Thus, when the Commissioner asserts that the FDA will "aid in the effort to bring novel therapies to patients as quickly, and as safely, as possible," it simply belies history. Likewise, overtures made toward any potential regulations being congruent with the 21st Century Cures Act are dubious. The spirit of the Cures Act is clear; it calls for the "accelerated approval for advanced regenerative therapies."

More federal regulation rarely, if ever, leads to acceleration of anything. In fact, it almost always tends to slow things down. Thus, unnecessary and unreasonably burdensome regulation by the FDA could contravene the will of Congress, and thus the will of the American people.

Texas Legalizes 'Personal' Stem Cell Therapy

Furthermore, the FDA's prospective regulatory guidance must be viewed in the context of recent events in Texas. On June 13, Texas governor Greg Abbot signed HB 810 into law, which made Texas the first state to legitimize the use of personal stem cell therapies statutorily. The signing of the bill was celebrated not only by stem cell advocates, but by the countless Americans who suffer from chronic, debilitating conditions for which the current medical services delivery model can offer only surgery and medication. For many, it was a monumental step forward toward fulfilling the promise of regenerative medicine and realization of true health care.

However, the FDA may have seen this move as reinforcing a "wild west" stem cell landscape, a landscape which it believes it must police.

All of us, including FDA officials, should be reminded that on February 28, at President Trump's first State of the Union speech (and on Rare Disease Day), the President took note of Sarah Hughes, a young attendee who had used her own stem cells to successfully treat Pompes Disease.The therapy normalized her immune system, alleviated her symptoms and helped reduce her medications from 22 to 8.

We must also remember the promise President Trump made to America's military veterans, many of whom suffer from painful, debilitating conditions that may be treated or cured by stem cells. President Trump cares deeply about veterans' health. He recently signed the Veterans Appeals Improvement and Modernization Act, which streamlines the process of veterans appealing claims over disability benefits. He also signed a bill that will let more veterans bypass the Department of Veterans Affairs and instead receive treatment from private doctors.

Finally, he signed legislation approving new tools to expand the VA's existing Telehealth Services, so veterans can schedule appointments and have video consultations from their mobile phones. It seems obvious that President Trump would never support restricting veterans' access to the medical care they need, including stem cells.

I believe that President Trump, through his devotion to our veterans, the Congress through the Cures Act, and the American people through their need for medical alternatives, would strongly disagree with any unreasonable curtailment of stem cell therapies.

The FDA must not defer to the opinion of "industry," and must prioritize the needs of Americans like Sarah Hughes and our suffering wounded warriors. People are in pain and pills cant always help them.

View post:
FDA Should Tread Carefully with Stem Cell Regulation - Pain News Network

Running Doc on how to treat Plantar Fasciitis – New York Daily News

NEW YORK DAILY NEWS

Sunday, August 27, 2017, 6:00 AM

Dear Running Doc:

Good afternoon. I hope you are having a fun weekend. I have had PF for 1.5 years now. I have tried stretching, cortisone, PRP injections, etc. and nothing has worked.

I love to run but had to give up last year and would love to get back to running. I have tried a few orthotics but have not tried custom fitted ones. What would you recommend? I live in Houston. I have seen a few foot and ankle surgeons but nothing has worked.

Thank you for your advice. Where is your office? Do you treat people in your office for PF?

Best, Jeff W., Houston, TX

I and the New York Daily News hope you and family are safe during this horrific storm.

The good news is your PF (Plantar Fasciitis) should not prevent you from running for more than three weeks. In my office practice in New York City, no one has had to give up running due to Plantar Fasciitis.

Plantar Fasciitis is an inflammation of tight connective tissue on the bottom of the foot making up its arch. A simple routine of ice, stretching, golf ball exercise, custom orthotics and sometimes PRP is all that is needed to get you back to run soon. Lets go through them to be sure you are doing them correctly. Leaving one out may cause the Plantar Fasciitis to linger.

Ice: You must ice the painful area for 20 minutes twice a day. Use a Ziploc freezer bag filled with ice and water. The water raises the temperature to 32 degrees to prevent freezer burn. Just plant your foot on the ice water bag in the morning after you have woken up and the evening before you go to sleep. Avoid those ice contraptions that are too cold.

Stretching: The Plantar Fascia connective tissue attaches around the heal bone to the calf muscles. It acts as a fulcrum (as we learned in high school). Therefore, stretching both the calf muscles (gastroc and soleus) helps loosen the tight Plantar Fascia. Wall push-ups with the knee both straight and bent should accomplish this. When the Plantar Fascia is less tight, there is less inflammation.

Golf Ball Exercise: A hard golf ball rolled back and forth over the most painful part of your arch for 30 minutes daily should do the trick. Remember with this exercise that your condition will hurt more before it hurts less. Dont get discouraged. Some people use a frozen water bottle for this exercise. In my experience, using a golf ball once a day and doing the ice separately twice a day works better than trying to combine these two steps together.

Custom Orthotics: Custom full-length flexible orthotics are a necessary step to combat Plantar Fasciitis. They stabilize the ligaments and prevent it from coming back. Over-the-counter orthotics are as good as over-the-counter glasses. You do need orthotics custom made properly.

Platelet Rich Plasma (PRP): First, Jeff, stay away from cortisone injections. Cortisone weakens soft tissues and, in my experience, causes an increased risk for further problems. If you do all the above steps, you may never need to get to PRP. If you have a bone spur coming out as a pointed projection from your heal, PRP may be necessary. Usually a PRP treatment is done with two treatments 24 to 72 hours apart.

I hope Jeff that the above information helps you to regain your running at a level that makes you comfortable. If you have any further questions, please do not hesitate to write again.

Enjoy the Ride!

***

Lewis G. Maharam, MD, FACSM is one of the worlds most extensively credentialed and well-known sports health experts. Better known as Running Doc, Maharam is author of Running Docs Guide to Healthy Running and past medical director of the NYC Marathon and Rock n Roll Marathon series. He is Medical Director of the Leukemia & Lymphoma Societys Team in Training program. He is also past president of the New York Chapter of the American College of Sports Medicine. Learn more at runningdoc.com.

Want your question answered in this column? Write to running doc at runningdoc@nydailynews.com.

See the rest here:
Running Doc on how to treat Plantar Fasciitis - New York Daily News